WASHINGTON, April 7, 2011 - As part of the Experimental Biology 2011 conference in Washington, D.C., next week, National Institutes of Health Director Francis Collins will discuss how the federal agency he leads is capitalizing on the gains made by the biomedical research community over the past few decades, describing his vision for translating work at the lab bench into therapeutics that will improve human health and reduce suffering here and across the globe.
Collins will give his talk, "NIH and the Biomedical Research Community: Opportunities and Concerns," at 6:30 p.m. Monday, April 11, in the Walter E. Washington Convention Center, where thousands of scientists will have convened at the conference to showcase cutting-edge technologies and spread the news of recent research breakthroughs.
"Biology is entering an era of seemingly limitless research opportunities, coupled with all-too-limited resources to pursue these opportunities," Collins wrote in an abstract for his forthcoming lecture. "In order for biomedical research to thrive in this challenging environment, the scientific community must adopt innovative technologies, bridge traditional disciplinary divides, and embrace creative funding solutions."
Collins' talk, which was invited by the American Society for Biochemistry and Molecular Biology, will examine the ways in which new paradigms for research, training and education will help biomedical science realize its full potential and encourage the next generation of researchers. He also will discuss new initiatives that, in this era of uncertain funding, will advance the careers of young investigators, while also supporting innovative yet potentially risky projects.
"The NIH looks to the ASBMB and other professional groups to foster collaboration across scientific disciplines and catalyze innovation along the research continuum," said Collins. "As part of our efforts to accelerate the movement of discoveries from the lab to the clinic, NIH recently announced plans to establish the National Center for Advancing Translational Sciences. I want to assure ASBMB members that this new center will serve to reinforce -- not reduce -- NIH's strong commitment to basic science. Advances in fundamental knowledge are the foundation for all translational research."
WHO: Francis Collins, director of the National Institutes of Health
WHAT: Plenary lecture at the American Society for Biochemistry and Molecular Biology annual meeting, which is part of the Experimental Biology 2011 conference
WHEN: 6:30 p.m. Monday, April 11
WHERE: Walter E. Washington Convention Center Ballroom C, on the third level
About Experimental Biology 2011
Experimental Biology is an annual gathering of six scientific societies that this year is expected to draw 13,000-plus independent scientists and exhibitors. The American Society for Biochemistry and Molecular Biology (ASBMB) is a co-sponsor of the meeting, along with the American Association of Anatomists (AAA), American Physiological Society (APS), American Society for Investigative Pathology (ASIP), American Society for Nutrition (ASN) and the American Society for Pharmacology and Experimental Therapeutics (ASPET).
More information about EB2011 for the media can be found on the press page: http://experimentalbiology.
About the American Society for Biochemistry and Molecular Biology
The ASBMB is a nonprofit scientific and educational organization with more than 12,000 members worldwide. Most members teach and conduct research at colleges and universities. Others conduct research in various government laboratories, at nonprofit research institutions and in industry. The Society's student members attend undergraduate or graduate institutions. For more information about ASBMB, visit www.asbmb.org.